Echosens

Echosens’ FibroScan® technology has become the global gold standard for non-invasive assessment of liver fibrosis and steatosis. It has been validated in over five thousand peer-reviewed publications and incorporated into more than two hundred international guidelines. The company’s solutions are used both in clinical practice and as standardized endpoints in clinical trials, supporting improved patient identification, monitoring, and trial efficiency for MASH/MASLD therapies. Over seven million exams are performed annually worldwide using their devices. Clinical results consistently show that FibroScan® provides accurate, reproducible measurements that reduce the need for invasive biopsies while improving early detection rates. The company’s diagnostic tools have also demonstrated value in diabetes management guidelines due to the high comorbidity with fatty liver diseases.